Monopar Therapeutics — Director's Dealing 2025

Apr 5, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2025-04-02

Reporting Person: Tactic Pharma LLC (10% Owner)
Reporting Person: Robinson Chandler (Director, Chief Executive Officer)
Reporting Person: Brown Michael J (Member of 10% Owner Group)
Reporting Person: O'Halloran Thomas V. (Member of 10% Owner Group)
Reporting Person: Mazar Andrew Paul (Member of 10% Owner Group)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-04-02	Common Stock	S	33334	$35	Disposed	822255	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.86, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein.